NCT00789763View on ClinicalTrials.gov

Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2012

Conditions
Pancreatic Cancer
Interventions
DRUG

Gemcitabine

300 mg/m2/one per week, i.v., during 5 weeks.

RADIATION

Radiotherapy

1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)

DRUG

Sorafenib

200-800 mg/day p.o. during 5 weeks

Trial Locations (4)

28046

Hospital Universitario La Paz, Madrid

46009

Hospital Universitario La Fe, Valencia

08025

Hospital de La Santa Creu I Sant Pau, Barcelona

08036

Hospital Clinic I Provincial, Barcelona

All Listed Sponsors
lead

Grupo Espanol Multidisciplinario del Cancer Digestivo

OTHER

NCT00789763 - Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma | Biotech Hunter | Biotech Hunter